PsychedelicNewsBreaks Archive - Page 37 of 70

ThursdayDec 02, 2021 10:00 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp’s Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to initiate in 2022, is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate Tryp’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. “The upcoming phase 2a study with…

ThursdayDec 02, 2021 8:30 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS. “Lucid-MS has demonstrated the potential to prevent the degradation and help re-establish myelin, which is evidenced by the functional recovery of mice as well as immunohistochemistry in this study, and several other studies in preclinical animal models,” said Dr. Lakshmi P. Kotra,…

WednesdayDec 01, 2021 2:54 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reimagining Mental Health, Addiction Treatment

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, recently filed a patent application covering bioavailability-enhancing, nanoemulsion-empowered formulations. The move followed on the heels of a previous announcement that the company had filed a final patent application for MYCO-003, one of its lead drug candidates. Nanoemulsion is an advanced drug delivery system that offers enhanced stability, fast digestibility, controlled release and protection against degradation. “Specifically, Mydecine is targeting the enhanced bioavailability and controlled capabilities of the nanoemulsion technology. The system’s controlled-release capability, for example, will…

WednesdayDec 01, 2021 2:38 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently submitted an Investigational New Drug (“IND”) application to the U.S. FDA to evaluate its TRP-8802 clinical candidate in a phase 2a clinical trial to explore psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. The study, which is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D., will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of comorbidities that include anxiety, depression, poor sleep quality and other conditions. Tryp expects to initiate the study in 2022, subject to a favorable…

TuesdayNov 30, 2021 1:07 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key FDA Approvals, Participation in Psychedelics Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received authorization from the U.S. Food and Drug Administration (“FDA”) for an investigator-initiated, randomized, placebo-controlled phase 2 clinical trial; the trial is designed to evaluate psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The company noted that the primary investigator for the trial, Dr. Anthony Back, received an investigational new drug ("IND") approval letter from the FDA, authorizing the trial. In addition, the study has received Institutional Review Board (“IRB”) approval at the University of Washington. Cybin also announced that CEO Doug Drysdale…

MondayNov 29, 2021 11:48 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Adelia Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has reported that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved key milestones. The milestones were outlined in the agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. Based on the agreement, 31,721.5 class B common shares of the company will be issued to Adelia shareholders as a result of relevant milestones being met. Adelia develops medicinal psychedelics designed to provide improved dosing efficacy and therapeutic indices that address unmet medical needs. The company’s primary focus is on the…

WednesdayNov 24, 2021 12:21 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Looking to Change Narrative in Treating Fibromyalgia, Chronic Pain

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is looking to transform the existing treatment of fibromyalgia, along with other forms of chronic pain, and relieve the suffering of millions of patients. To achieve this, the company is relying on the guidance of its scientific advisory board (“SAB”) as well as research-based work conducted in partnership with the University of Michigan (“U-M”). “According to Tryp’s internal analysis, over 4 million people suffer from fibromyalgia in the United States. Globally, the condition affects an estimated 3-6% of the population (roughly 232-465 million people). Unfortunately, despite the disease afflicting millions, researchers have not yet…

TuesdayNov 23, 2021 10:29 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Awards Grant for Psychedelic Treatment Clinic to Benefit Underserved Communities

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York. According to the update, the program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. “It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” said Dr. Alex Belser, chief clinical officer of Cybin.…

ThursdayNov 18, 2021 11:46 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CEO Discusses Blockbuster Drug Potential on MidasLetter Podcast

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent MidasLetter Live podcast. Mydecine’s CEO and Chairman Joshua Bartch joined the program to provide an overview of the company and the science behind its psychedelic compounds. “What we are showing in the efficacy rates that are coming out of that study are over three to five times what’s currently available of Chantix or a nicotine patch with a much safer drug,” Bartch said in discussing clinical trials for smoking cessation using…

ThursdayNov 18, 2021 10:53 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Unveils First-of-Its-Kind Family Support & Education Program

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that its chain of Ketamine Wellness Clinics (“KWC”) will be offering the industry’s first support and education program designed to support the family and loved ones of its patients. KWC, the country’s largest chain of wellness centers that provide ketamine treatments, launched its Family Support & Education program today; the free program is designed by medical professionals to help families, significant others and loved ones provide valuable support to patients who choose ketamine infusion treatments. In announcing the program,…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks